Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Tissue Analyses Indicate Survival Benefits for Lung Cancer Patients

By Drug Discovery Trends Editor | November 13, 2008

Taking small tissue samples from patients with lung cancer and examining them under a microscope (a procedure called histology) is now being utilized to better tailor the chemotherapy treatments to improve survival in some patients with non-small cell lung cancer, according to a study cosponsored by ASTRO, ASCO, IASLC and the University of Chicago.

Cancer researchers have begun to believe in a tailored approach to chemotherapeutic intervention based on the histology or tissue type in the treatment of non-small cell lung cancer. To prove this hypothesis, cancer researchers from Pennsylvania State Hershey Cancer Institute in Hershey, Pa., Medical University of Vienna in Vienna, Austria, University of Torino in Orbassano, Italy, and Eli Lilly and Company of Indianapolis, Ind., considered two large studies, each of which compared pemetrexed-based (chemotherapy-based) treatment to a control treatment. They analyzed each of these studies for the presence of a treatment-by-histology interaction. A treatment-by-histology interaction exists if the relative benefit of the pemetrexed-based treatment (compared to the control treatment) depends on histology. The analyses show that a strong treatment-by-histology interaction exists for both studies, indicating that pemetrexed-based treatment is more effective in patients with non-squamous histology as compared to squamous histology.

“Nonsquamous histology is predictive of improved efficacy of the chemotherapy agent pemetrexed in patients with non-small cell lung cancer,” said Chandra Belani, M.D., a lung cancer specialist from Pennsylvania State Hershey Cancer Institute. “This study is building the body of evidence showing that examining tissue types can help doctors find the most effective treatments for patients with lung cancer and other diseases.”

Release Date: November 13, 2008
Source: American Society for Therapeutic Radiology and Oncology


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE